# Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

> **NCT04538040** · PHASE4 · COMPLETED · sponsor: **Quest Clinical Research** · enrollment: 20 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch

## Key facts

- **NCT ID:** NCT04538040
- **Lead sponsor:** Quest Clinical Research
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-19
- **Primary completion:** 2021-11-11
- **Final completion:** 2021-11-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04538040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04538040, "Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04538040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*